Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, exemplifies our dedication to cutting-edge care for managing type 2 diabetes and weight
Interestingly, exendin-4 is similar in structure and function to GLP-1, but is resistant to degradation by DPP4, allowing exendin-4 to remain in circulation for hours rather than just a few minutes
It begins with a thorough understanding of your current metabolic profile and health history
Going from two pathways to three means your body encounters a completely new type of receptor activation (glucagon) that it has never experienced before, regardless of how long you have been on tirzepatide
Health regulatory agencies such as the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency of Japan (PMDA) evaluate data from clinical trials before approving the use of GLP-1 analogs for the treatment of diabetes and obesity
The gut microbiome produces metabolites such as short-chain fatty acids that influence metabolic signaling, immune communication, and gut barrier integrity
